modelDantronInclCombinations

Diagram of DantronInclCombinations

Extends from Pharmacolibrary.Drugs.ATC.A.A06AG03.

Information

name:DantronInclCombinations
ATC code:A06AG03
route:oral
compartments:1
dosage:50mg
volume of distribution:2.5L
clearance:1L/h/kg
other parameters in model implementation

Dantron (also known as danthron) is an anthraquinone derivative used as a stimulant laxative for the treatment of constipation. It has been used for patients requiring regular bowel evacuation, particularly in palliative care. Dantron has been withdrawn from use in several countries (including the USA and much of Europe) due to concerns over potential carcinogenicity, but remains available in the UK mainly for use in terminal care, usually in combination with other agents.

Pharmacokinetics

No pharmacokinetic models with quantitative parameters reported in humans were found in published literature for dantron or dantron combinations (A06AG03). Parameter values below are estimated based on general pharmacokinetics of stimulant laxatives and anthraquinone derivatives, and representative values for oral bioavailability and disposition. Typical dosing is in adult patients; no sex or condition specificity.

References

    Parameters

    TypeNameDefaultDescription
    Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
    Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
    Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
    Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
    Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
    Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
    Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
    Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
    IntegeradminCount (from PK_1C)8number of dose administered (1)
    Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
    Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
    Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
    Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
    Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
    Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

    Connectors

    TypeNameDefaultDescription
    Types.ConcentrationOutputC_central (from PK_1C)
    Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

    Components

    TypeNameDefaultDescription
    Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
    Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
    Sources.PeriodicDoseperiodicDose (from PK_1C)
    Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

    Revisions

    • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)